These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 31484245)

  • 1. [The clinical experience of pirfenidone based on corticosteroids and immunosuppressant treatment for interstitial pneumonia with autoimmune features].
    Huang H; Sun YX; Li S; Shao C; Xu K; Xu ZJ
    Zhonghua Jie He He Hu Xi Za Zhi; 2019 Sep; 42(9):700-704. PubMed ID: 31484245
    [No Abstract]   [Full Text] [Related]  

  • 2. [Clinical experience with pirfenidone for the treatment of idiopathic pulmonary fibrosis].
    Bonella F; Wessendorf TE; Costabel U
    Dtsch Med Wochenschr; 2013 Mar; 138(11):518-23. PubMed ID: 23423955
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pirfenidone in idiopathic pulmonary fibrosis: real-life experience from a German tertiary referral center for interstitial lung diseases.
    Oltmanns U; Kahn N; Palmowski K; Träger A; Wenz H; Heussel CP; Schnabel PA; Puderbach M; Wiebel M; Ehlers-Tenenbaum S; Warth A; Herth FJ; Kreuter M
    Respiration; 2014; 88(3):199-207. PubMed ID: 25115833
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical features and natural history of interstitial pneumonia with autoimmune features: A single center experience.
    Chartrand S; Swigris JJ; Stanchev L; Lee JS; Brown KK; Fischer A
    Respir Med; 2016 Oct; 119():150-154. PubMed ID: 27692137
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical features, risk factors, and outcomes of patients with interstitial pneumonia with autoimmune features: a population-based study.
    Dai J; Wang L; Yan X; Li H; Zhou K; He J; Meng F; Xu S; Liang G; Cai H
    Clin Rheumatol; 2018 Aug; 37(8):2125-2132. PubMed ID: 29667101
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interstitial pneumonia with autoimmune features: Clinical, radiologic, and histological characteristics and outcome in a series of 57 patients.
    Ahmad K; Barba T; Gamondes D; Ginoux M; Khouatra C; Spagnolo P; Strek M; Thivolet-Béjui F; Traclet J; Cottin V
    Respir Med; 2017 Feb; 123():56-62. PubMed ID: 28137497
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic Approach to Adult Fibrotic Lung Diseases.
    Adegunsoye A; Strek ME
    Chest; 2016 Dec; 150(6):1371-1386. PubMed ID: 27521738
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pirfenidone treatment of idiopathic pulmonary fibrosis.
    Azuma A
    Ther Adv Respir Dis; 2012 Apr; 6(2):107-14. PubMed ID: 22333982
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interstitial pneumonia with autoimmune features and histologic usual interstitial pneumonia treated with anti-fibrotic versus immunosuppressive therapy.
    Yamano Y; Kataoka K; Takei R; Sasano H; Yokoyama T; Matsuda T; Kimura T; Mori Y; Furukawa T; Fukuoka J; Johko T; Kondoh Y
    Respir Investig; 2023 May; 61(3):297-305. PubMed ID: 36863306
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serological and morphological prognostic factors in patients with interstitial pneumonia with autoimmune features.
    Ito Y; Arita M; Kumagai S; Takei R; Noyama M; Tokioka F; Nishimura K; Koyama T; Notohara K; Ishida T
    BMC Pulm Med; 2017 Aug; 17(1):111. PubMed ID: 28807021
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Open-label compassionate use one year-treatment with pirfenidone to patients with chronic pulmonary fibrosis.
    Nagai S; Hamada K; Shigematsu M; Taniyama M; Yamauchi S; Izumi T
    Intern Med; 2002 Dec; 41(12):1118-23. PubMed ID: 12521199
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pirfenidone in patients with rapidly progressive interstitial lung disease associated with clinically amyopathic dermatomyositis.
    Li T; Guo L; Chen Z; Gu L; Sun F; Tan X; Chen S; Wang X; Ye S
    Sci Rep; 2016 Sep; 6():33226. PubMed ID: 27615411
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pirfenidone for acute exacerbation of idiopathic pulmonary fibrosis: A retrospective study.
    Furuya K; Sakamoto S; Shimizu H; Sekiya M; Kinoshita A; Isshiki T; Sugino K; Matsumoto K; Homma S
    Respir Med; 2017 May; 126():93-99. PubMed ID: 28427556
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of pirfenidone in the treatment of interstitial pneumonia with autoimmune features.
    Chen T; Li QH; Zhang Y; Yin CS; Weng D; Zhou Y; Hu Y; Shi JY; Chen YN; Ye S; Wang XD; Wu CY; Huang Y; Zhang AH; Li HP
    Clin Exp Rheumatol; 2022 Mar; 40(3):560-567. PubMed ID: 33822701
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors of the clinical effects of pirfenidone on idiopathic pulmonary fibrosis.
    Arai T; Inoue Y; Sasaki Y; Tachibana K; Nakao K; Sugimoto C; Okuma T; Akira M; Kitaichi M; Hayashi S
    Respir Investig; 2014 Mar; 52(2):136-43. PubMed ID: 24636270
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pulmonary fibrolysis in a patient with idiopathic pulmonary fibrosis: improvement of clinical and radiological pattern after treatment with pirfenidone.
    Varone F; Mastrobattista A; Franchi P; Viglietta L; Poletti V; Tomassetti S; Dubini A; Tagliaboschi L; Calandriello L; Farchione A; Larici AR
    Clin Respir J; 2018 Jan; 12(1):347-351. PubMed ID: 27322356
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Update in Interstitial Lung Disease 2014.
    Belloli EA; Martinez FJ; Flaherty KR
    Am J Respir Crit Care Med; 2015 Sep; 192(5):538-43. PubMed ID: 26561676
    [No Abstract]   [Full Text] [Related]  

  • 18. Case Report: Successful Treatment of Refractory Interstitial Lung Disease With Cyclosporine A and Pirfenidone in a Child With SLE.
    Deng L; Chen Y; Hu X; Zhou J; Zhang Y
    Front Immunol; 2021; 12():708463. PubMed ID: 34671344
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of pirfenidone in idiopathic pulmonary fibrosis in clinical practice.
    Okuda R; Hagiwara E; Baba T; Kitamura H; Kato T; Ogura T
    Respir Med; 2013 Sep; 107(9):1431-7. PubMed ID: 23849626
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pirfenidone Improves Familial Idiopathic Pulmonary Fibrosis without Affecting Serum Periostin Levels.
    Koga Y; Hachisu Y; Tsurumaki H; Yatomi M; Kaira K; Ohta S; Ono J; Izuhara K; Dobashi K; Hisada T
    Medicina (Kaunas); 2019 May; 55(5):. PubMed ID: 31108995
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.